Date:3/14/2010

R3i is responding to this critically important clinical problem. 'Given the magnitude of the global epidemic of type 2 diabetes - especially in developing regions - targeting atherogenic dyslipidemia is crucial. As the only independent global research foundation focusing on this issue, the R3i is urgently developing recommendations for evidence-based strategies to reduce residual vascular risk. Currently, we are conducting the first world-wide epidemiological study, REALIST, to establish the prevalence of atherogenic dyslipidemia and consequent residual risk of cardiovascular events. Now, as a result of ACCORD Lipid, we will also initiate a meta-analysis of the atherogenic dyslipidemic subgroups of patients (high TG and/or low HDL-C) in previous fibrate studies,' said Professor Fruchart.

Notes to Editors

About ACCORD

The ACCORD study was sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH) in the U.S, and was conducted across the U.S. and Canada. The key question addressed in the ACCORD Lipid treatment arm was whether the combination of fenofibrate plus simvastatin, i.e. targeting elevated TG and low HDL-C in addition to LDL-C, was more effective in reducing cardiovascular events than statin therapy alone in a cohort of 5,518 high-ri
'/>"/>

SOURCE Residual Risk Reduction initiative (R3i) Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
2. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
7. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
8. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
9. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
10. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference